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Pre-diagnosis oophorectomy, estrogen therapy
and mortality in a cohort of women diagnosed
with breast cancer
Hazel B Nichols1*, Amy Trentham-Dietz2,3, Polly A Newcomb4, Kathleen M Egan5, Linda J Titus6,
John M Hampton3 and Kala Visvanathan1,7
Abstract
Introduction: Pre-diagnosis oophorectomy and estrogen therapy could impact mortality due to breast cancer and
cardiovascular disease (CVD) among breast cancer survivors. Elective bilateral oophorectomy at the time of
hysterectomy for benign conditions is not uncommon among US women.
Methods: We examined the association between pre-diagnosis total abdominal hysterectomy with bilateral salpingo-
oophorectomy (TAHBSO) and both overall and cause-specific mortality in the Collaborative Breast Cancer Studies cohort.
Medical history and prior estrogen use were collected during standardized telephone interviews. Vital status, including
date and cause of death, was obtained by linkage with the National Death Index. Multivariate hazard ratios (HR) and 95%
confidence intervals (CI) for cause-specific mortality were calculated using Cox proportional hazards regression.
Results: Seventeen percent (N = 1,778) of breast cancer survivors (mean age at diagnosis = 63.5) reported pre-diagnosis
TAHBSO. During follow-up (mean = 9.5 years), 2,856 deaths occurred, including 1,060 breast cancer deaths and 459 CVD
deaths. Breast cancer deaths occurred a median of 5.1 years after diagnosis; CVD deaths occurred further from diagnosis
(median = 9.7 years). Women who reported pre-diagnosis TAHBSO had a 16% decrease in all-cause mortality (HR = 0.84;
95% CI: 0.76, 0.92) compared to those with an intact uterus and ovaries. This overall decrease reflected a 27% lower
breast cancer mortality among women who never used postmenopausal hormones (HR = 0.73; CI: 0.55, 0.96) and 43%
lower CVD risk among women who reported using estrogen (HR = 0.57; CI: 0.39, 0.83) after TAHBSO.
Conclusions: Information on prior TAHBSO and estrogen use can inform risk of death from both breast cancer and
cardiovascular disease among breast cancer survivors.
Introduction
With a growing population of >2.7 million breast cancer
survivors in the United States [1], identifying factors that
contribute to long-term mortality is of increasing im-
portance. Pre-diagnosis behaviors can impact survival
from breast cancer and medical conditions, such as car-
diovascular disease [2-5]. For example, higher levels of
physical activity and lower body mass index (BMI) prior
to breast cancer diagnosis are associated with improved
all-cause and cause-specific survival [3,6-8]. A beneficial
effect of pre-diagnosis bilateral oophorectomy on breast
cancer-specific mortality has been reported in some [9],
but not all [10], studies of women in the general popula-
tion and among patient populations of women at high
risk of developing breast cancer due to BRCA1/2 muta-
tion status [11]. However, all-cause mortality among
women with breast cancer could be adversely affected by
increases in deaths due to heart disease, stroke, or fracture
that may be associated with ovarian removal [10,12-15].
These opposing risks and benefits may be further influ-
enced by the use of unopposed estrogen therapy after
surgery [2,10,12,14,16-18].
In the United States, total abdominal hysterectomy
with bilateral salpingo-oophorectomy (TAHBSO) is often
performed for benign conditions such as uterine fibroids;
an estimated 15% of US women have their uterus and
ovaries removed by age 60 [19,20]. Identifying prognostic
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factors at breast cancer diagnosis for both cancer and
non-cancer outcomes can inform risk of death among
breast cancer survivors and guide appropriate chronic dis-
ease prevention strategies. To examine the impact of pre-
diagnosis TAHBSO and estrogen therapy on cause-specific
mortality, we analyzed data from a cohort of 10,443 US
women diagnosed with postmenopausal invasive breast
cancer.
Methods
This analysis was performed with data from the Collab-
orative Breast Cancer Study Cohort [6,21,22]. Cohort
members participated as cases in one of four con-
secutive population-based case-control studies of inva-
sive breast cancer. Participant identification, enrollment,
and data collection procedures were maintained across
studies. All participants provided verbal informed con-
sent at the time of the phone-based survey. Standard
protocols for each study were approved by Institutional
Review Boards at the University of Wisconsin-Madison,
Harvard School of Public Health, and Dartmouth Med-
ical School.
Study population
Study participants were female residents of Wisconsin,
Massachusetts, or New Hampshire with an incident inva-
sive breast cancer reported to each state’s cancer registry
during the study enrollment years. Eligibility was limited
to women with listed telephone numbers, driver’s licenses
(if younger than 65 years), and registry-reported dates of
diagnosis. Women ages 50 to 79 were eligible in the first
study (1992 to 1995); and ages 20 to 69 in subsequent
studies (1997 to 2001; 2001 to 2004; 2004 to 2007). During
1992 to 2001 participants were enrolled in Wisconsin,
Massachusetts, and New Hampshire; in 2001 to 2007
women were enrolled in Wisconsin only. Across the four
studies, 21,713 eligible participants were identified. Physi-
cians refused contact with 359 (1.7%), 743 (3.4%) were de-
ceased, 624 (2.9%) could not be located and 2,794 (12.9%)
refused to participate. Therefore, 17,193 (79.2%) eligible
breast cancer survivors were interviewed. Thirty-eight in-
terviews were considered unreliable by the interviewers,
leaving 17,155 interviews available for analysis.
Exposure assessment
In each study, participants completed a 40-minute struc-
tured telephone interview that elicited detailed informa-
tion on lifestyle and demographic factors, postmenopausal
hormone use, and personal and family medical history.
Study participants reported whether they had surgery to
remove the uterus or ovaries, the type of surgery (hys-
terectomy and/or oophorectomy, including number of
ovaries removed), and age at surgery. Participants were
asked a standard history of postmenopausal hormone use
including formulation, route of administration, age started,
frequency of each episode of use, total duration, and time
since last use.
In three of the four pooled studies (1992 to 1995; 1997
to 2001; 2001 to 2004), menopause was defined as the
absence of menses for six consecutive months not attrib-
utable to surgery, chemotherapy, radiation, or other rea-
sons. In the most recent study (2004 to 2007), menopause
was defined as 12 consecutive months without menses. In
all studies, women who reported bilateral oophorectomy
prior to breast cancer diagnosis were categorized as post-
menopausal. BMI was calculated as weight (kg)/tallest
adult height (m)2 during the one- to five-year period prior
to breast cancer diagnosis.
Outcome assessment
Vital status information, including date and underlying
cause of death, was collected through December 31,
2009 through linkage with the National Death Index.
Cause of death was categorized according to the Inter-
national Classification of Disease (ICD-10) code as
breast cancer-specific mortality (C50), cardiovascular
(CVD) mortality (I00 to I09, I11, I13, I20 to 51), stroke
mortality (I60 to I69), or all-cause mortality [23].
Population for analysis
For consistency in ages at enrollment across studies, this
pooled analysis was limited to women age 50 and older
at breast cancer diagnosis (N = 13,253). We further ex-
cluded women who were premenopausal at diagnosis
(N = 1,352) or had unknown menopausal status (N = 620),
or who had a previous history of cancer (except non-
melanoma skin cancer) (N = 614). Ninety-three records
from women with discordant ages at bilateral oophor-
ectomy and hysterectomy and 41 records with missing
ages for both procedures were excluded. To exclude
gynecologic surgeries performed as part of breast can-
cer treatment, 84 women who reported bilateral oo-
phorectomy or hysterectomy at the same age or after
breast cancer diagnosis were excluded. Six records were
excluded based on partial interview completion. After
these exclusions were applied, 10,443 women were eli-
gible for analysis. Among the eligible breast cancer survi-
vors, 1,778 (17.0%) reported having a prior TAHBSO and
6,913 (66.2%) reported having an intact uterus and ovar-
ies at breast cancer diagnosis; therefore, records from
8,691 breast cancer survivors contributed to this analysis.
The remaining 1,752 records included 1,641 women who
reported hysterectomy alone or unilateral oophorec-
tomy with or without hysterectomy, and 111 women
with missing information on previous gynecologic surgery.
On average, women were interviewed 1.3 years (standard
deviation (SD) = 0.5; range: 0.2 to 4.9) after breast cancer
diagnosis.
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Statistical analysis
All mortality comparisons were made relative to women
who reported having an intact uterus and ovaries and
never using postmenopausal hormones at breast cancer
diagnosis. Kaplan Meier curves were produced to display
mortality curves; formal statistical comparison of the dif-
ference in slopes was conducted with log rank tests [24].
For survival analyses, the time scale was defined as time
since breast cancer diagnosis (years) and person-time
was accrued from date of interview. Participants either
developed the event of interest (breast cancer mortality/
cardiovascular disease mortality/all-cause mortality) or
were administratively censored on December 31, 2009.
In statistical models of mortality within five years of diag-
nosis, person-time was accrued from date of interview to
the event of interest or administrative censoring at five
years after the diagnosis date. For analyses of five-year sur-
vivors, person-time was accrued from five years after diag-
nosis until the event of interest or administrative censoring
on December 31, 2009.
Cox proportional hazards regression was used to calcu-
late multivariate hazard ratios (HR) for all-cause mortality.
The Fine and Gray method was used to fit proportional
cumulative incidence-associated subhazards regression
models for breast cancer and CVD-specific mortality to
account for non-breast and non-CVD disease deaths as
competing events [25,26]. A priori, final estimates were
adjusted for stage of diagnosis, state, study enrollment
years, age at diagnosis, BMI one to five years before breast
cancer diagnosis, smoking status at breast cancer diagno-
sis, and family history of breast cancer as potential con-
founders. P values ≤0.05 were considered to be statistically
significant. All statistical analyses were performed with
Stata 12 software (StataCorp, College Station, TX, USA).
Sensitivity analyses
Across the four studies, the majority of participants were
enrolled in Wisconsin (69%) and were diagnosed with
local invasive disease (64%). We conducted sensitivity
analyses to evaluate whether inclusion of participants in
Massachusetts and New Hampshire or those with regional
or distant disease influenced our results.
Results
A total of 2,856 deaths occurred during 82,201 person-
years (mean = 9.5 years; SD = 4.8) contributed by 8,691
women. The greatest proportion (37.1%) of deaths were
due to breast cancer (N = 1,060), followed by coronary
heart disease (16.1%, N = 459) and stroke (5.4%, N = 153).
Study participant characteristics according to gyneco-
logic surgery status are presented in Table 1. Overall, the
exposure groups had similar distributions for age at
breast cancer diagnosis, state of residence, and parity.
TAHBSO was more frequently reported in earlier study
years. Women who had undergone TAHBSO were less
likely to smoke, had lower education, and were more
likely to be overweight or obese and have a first-degree
family history of breast cancer than women who reported
having an intact uterus and ovaries. Use of estrogen-only
postmenopausal hormone formulations was largely re-
stricted to women who underwent TAHBSO compared
to women with an intact uterus and ovaries (estrogen-
only formulations are not recommended for women with
an intact uterus due to the increased risk of endometrial
cancer). Women who reported TAHBSO were slightly
more likely to be diagnosed with local stage breast can-
cer relative to women with an intact uterus and ovaries
(Table 1).
All-cause mortality
TAHBSO was associated with a 16% decrease in mortal-
ity from all causes (HR = 0.84; 95% confidence interval
(CI): 0.76, 0.92). All-cause mortality did not appear to
vary according to age at surgery. The inverse association
between pre-diagnosis TAHBSO and all-cause mortality
was of greater magnitude among women who reported
using estrogen therapy (HR = 0.78; 95% CI: 0.69, 0.89)
compared to no estrogen use (HR = 0.92; 95% CI: 0.80,
1.05) (Table 2, Figure 1A). All-cause mortality risk esti-
mates were similar across categories of estrogen dur-
ation (HR = 0.81; 95% CI: 0.65, 1.02 for 0.5 to 4.9 years;
HR = 0.75; 95% CI: 0.56, 0.99 for 5 to 9.9 years; and
HR = 0.77; 95% CI: 0.65, 0.92 for ≥10 years) (Table 2).
All-cause mortality among women who underwent
pre-diagnosis TAHBSO and used estrogen therapy ap-
peared to vary with follow-up time (Figure 1A): during
the first four years after breast cancer diagnosis, estrogen
use did not seem to influence mortality, whereas ap-
proximately five years after breast cancer diagnosis es-
trogen therapy appeared to confer a survival advantage.
Therefore, we examined five-year mortality risk separ-
ately from deaths that occurred less than five years after
diagnosis. TAHBSO alone was not associated with de-
creased all-cause mortality within the first five years
after diagnosis (HR = 0.93; 95% CI: 0.78, 1.10). However,
among five-year breast cancer survivors, we observed a
20% decrease in mortality risk among women who re-
ported pre-diagnosis TAHBSO (HR = 0.80; 95% CI: 0.72,
0.90), particularly among women who also used estrogen
therapy (HR = 0.72; 95% CI: 0.62, 0.85) (Table 3).
Mortality due to causes other than breast cancer may
be more common among women diagnosed at ages 65
and older [4,27]. With this consideration, we also evalu-
ated HRs for cause-specific mortality according to age at
diagnosis. Overall, TAHBSO was associated with decreased
all-cause mortality among both women who were diag-
nosed at ages 50 to 64 (HR = 0.78; 95% CI: 0.66, 0.91) and
ages ≥65 (HR = 0.86; 95% CI: 0.77, 0.97). When evaluated
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Table 1 Participant characteristics according to gynecologic surgery history prior to breast cancer diagnosis,
Collaborative Breast Cancer Studies
TAHBSOa (N = 1,778) Intact uterus and ovaries (N = 6,913) P-valueb
Age at diagnosis, mean (SD) 63.5 6.9 63.2 6.8 0.08
Study enrollment years, %
1992-1995 876 49.3 3,177 46.0
0.01
1997-2001 527 29.6 2,071 30.0
2001-2004 172 9.7 690 10.0
2004-2007 203 11.4 975 14.1
State, %
WI 1,205 67.8 4,787 69.2
0.3MA 433 24.4 1,568 22.7
NH 140 7.9 558 8.1
Smoking status at diagnosis, %
Never 955 53.7 3,237 46.8
<0.001
Former 564 31.7 2,376 34.4
Current 256 14.4 1,258 18.2
Missing 3 0.2 42 0.6
Education, %
High school diploma or less 1,070 60.2 3,924 56.8
0.04Some college 383 21.5 1,538 22.2
College degree or higher 320 18.0 1,424 20.6
Parity, mean (SD)c 3.1 1.6 3.1 1.6 0.5
Body mass index, %
Underweight (< 18.5 kg/m2) 24 1.3 102 1.5
0.002
Normal (18.5-24.9 kg/m2) 641 36.1 2,813 40.7
Overweight (25-29.9 kg/m2) 626 35.2 2,276 32.9
Obese (≥ 30 kg/m2) 450 25.3 1,542 22.3
Missing 37 2.1 180 2.6
Family history of breast cancer, %
Yes 418 23.5 1,445 20.9 0.04
Missing 27 1.5 127 1.8
Postmenopausal hormone therapy, %
None 539 30.3 4,541 65.7
<0.001
Estrogen only 1,033 58.1 399 5.8
Estrogen plus progestin only 52 2.9 1,561 22.6
Multiple/other formulations 129 7.3 336 4.9
Stage, %
Local 1,183 66.5 4,421 64.0
0.04
Regional 423 23.8 1,797 26.0
Distant 23 1.3 140 2.0
Unknown 149 8.4 555 8.0
Histology, %
Ductal 1,407 79.1 5,429 78.5
0.01Lobular/non-ductal 122 6.9 615 8.9
Other 244 13.7 847 12.3
aTAHBSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy; bP value for t tests of continuous variables and chi-square tests of categorical variables;
camong parous women only (N = 1,541 (86.7%) who reported TAHBSO; N = 6,016 (87.0%) with intact uterus and ovaries).
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according to estrogen use, estimates remained statistically
significant only among estrogen users (HR = 0.75; 95% CI:
0.61, 0.92 among women ages 50 to 64 and HR = 0.80;
95% CI: 0.67, 0.94 among women ≥65) (Table 3).
Breast cancer-specific mortality
In multivariate competing-risk regression models, pre-
diagnosis TAHBSO was associated with a 24% reduction
in breast cancer mortality (HR = 0.76; 95% CI: 0.64,
0.90). No variation was observed according to age at sur-
gery. When evaluated according to estrogen use, de-
creased breast cancer mortality risk was observed among
women who reported TAHBSO and never used hor-
mones (HR = 0.73; 95% CI: 0.55, 0.96) but not among
women who used unopposed estrogens (HR = 0.97; 95%
CI: 0.80, 1.18) (Table 2, Figure 1B). We did not observe a
consistent pattern of breast cancer-specific mortality risk
according to duration of estrogen use (Table 2).
When evaluated according to time since diagnosis,
TAHBSO was associated with a suggested decrease
in breast cancer mortality among five-year survivors
(HR = 0.81; 95% CI: 0.64, 1.02 for TAHBSO overall;
HR = 0.69; 95% CI: 0.46, 1.01 for women who reported
TAHBSO and never hormone use). In analyses stratified
according to age at diagnosis, TAHBSO was associated
with statistically significant reductions in breast cancer
mortality only among women ages 50 to 64 at diagnosis
(HR = 0.78; 95% CI: 0.62, 0.98) (Table 3).
Cardiovascular disease-specific mortality
Overall, the association between TAHBSO and risk
of death due to CVD was not statistically significant
(HR = 0.84, 0.67, 1.06) in multivariate competing-risk
regression models. When evaluated according to age at
surgery, TAHBSO at ages ≤45 years was not related to
CVD mortality (HR = 1.04; 95% CI: 0.75, 1.44), but de-
creased CVD mortality was observed among women
who reported TAHBSO at older ages (HR = 0.73; 95%
CI: 0.54, 0.98). Women who reported TAHBSO and es-
trogen therapy use had a 43% decrease in CVD mortality
(HR = 0.57; 95% CI: 0.39, 0.83); and those who reported
at least 10 years of estrogen use had an estimated 55% re-
duction in CVD mortality (HR = 0.45; 95% CI: 0.26,
0.78). Conversely, women who reported TAHBSO and
did not use estrogen had a non-statistically significant
19% increase in CVD mortality risk (95% CI: 0.89, 1.58)
(Table 2, Figure 1C).
Fewer CVD deaths occurred within the first five years
of diagnosis or among women who were 50 to 64 years
at breast cancer diagnosis compared to five-year survi-
vors and older women. Among five-year breast cancer
survivors, those who reported TAHBSO and unopposed
estrogen use had an estimated 47% reduction in CVD
mortality (HR = 0.53; 95% CI: 0.35, 0.81). Sample sizes
were insufficient to calculate fully adjusted HRs for CVD
mortality among women ages 50 to 64 at diagnosis, esti-
mates in this group are adjusted for study enrollment
years, age and stage at diagnosis only. A 68% decrease in
CVD mortality was estimated among women ages 50 to 64
at diagnosis who reported previous TAHBSO and estrogen
use (HR = 0.32; 95% CI: 0.13, 0.80). Among women who
were ≥65 at diagnosis, we observed a 35% decrease in
CVD mortality associated with TAHBSO and estrogen use
(HR = 0.65; 95% CI: 0.43, 0.98) (Table 3).
Table 2 Hazard ratios (95% CI) for mortality according to gynecologic surgery and estrogen use prior to breast cancer
diagnosis, Collaborative Breast Cancer Studies
Person-years All-cause mortality Breast cancer mortality Cardiovascular disease mortality
Deaths HR (95% CI)a Deaths HR (95% CI)b Deaths HR (95% CI)b
Intact uterus and ovaries, never hormone use 43,221 1,877 1 661 1 326 1
TAHBSOc 17,549 557 0.84 (0.76, 0.92) 198 0.76 (0.64, 0.90) 94 0.84 (0.67, 1.06)
Age at surgery:
≤ 45 years 6,459 218 0.86 (0.75, 0.99) 71 0.85 (0.66, 1.09) 43 1.04 (0.75, 1.44)
> 45 years 11,090 339 0.82 (0.73, 0.92) 127 0.86 (0.71, 1.05) 51 0.73 (0.54, 0.98)
Unopposed estrogen use:
Never used hormones 5,397 241 0.92 (0.80, 1.05) 59 0.73 (0.55, 0.96) 58 1.19 (0.89, 1.58)
Used unopposed estrogen 10,245 270 0.78 (0.69, 0.89) 120 0.97 (0.80, 1.18) 31 0.57 (0.39, 0.83)
Duration of estrogen use:
6 months- 4.9 years 2,765 80 0.81 (0.65, 1.02) 39 0.73 (0.56, 0.96) 12 0.72 (0.41, 1.29)
5 - 9.9 years 2,349 49 0.75 (0.56, 0.99) 23 1.19 (0.84, 1.66) 6 0.68 (0.30, 1.55)
≥ 10 years 5,131 141 0.77 (0.65, 0.92) 58 0.76 (0.50, 1.19) 13 0.45 (0.26, 0.78)
aHazard ratios adjusted for age, study enrollment years, state, body mass index, cigarette smoking, family history of breast cancer, and stage at diagnosis;
bcumulative incidence subhazard ratios adjusted for age, study enrollment years, state, body mass index, cigarette smoking, family history of breast cancer, and
stage at diagnosis; cTAHBSO, total abdominal hysterectomy and bilateral salpingo-oophorectomy.
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Figure 1 Cumulative mortality due to (A) all causes, (B) breast cancer, and (C) cardiovascular disease. Mortality curves are shown
according to pre-diagnosis surgery status: intact uterus and ovaries (‘no surgery’) versus total abdominal hysterectomy with bilateral oophorectomy
(‘TAHBSO’), and unopposed estrogen use (never/ever).
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In sensitivity analyses restricted to participants resid-
ing in Wisconsin (N = 5,992) or those with local disease
(N = 5,604), our findings were essentially unchanged com-
pared to the overall analysis.
Discussion
In this study, postmenopausal women who had a hyster-
ectomy with bilateral oophorectomy prior to breast
cancer diagnosis had an estimated 16% reduction in
all-cause mortality and 24% decrease in breast cancer
mortality compared to women who had an intact uterus
and never used hormones, irrespective of age at surgery.
Cause-specific mortality associations differed according
to post-surgical estrogen use. Breast cancer mortality
was lowest among those who did not use estrogens after
surgery, while cardiovascular disease and all-cause mor-
tality were lowest among estrogen users. These patterns
were more apparent among five-year breast cancer sur-
vivors compared to women who were within five years
of a breast cancer diagnosis. These findings indicate that
prior oophorectomy and estrogen use can impact cause
of death among breast cancer survivors.
Results from historical [9] and recent [10,12] studies
examining the association between pre-diagnosis bilateral
oophorectomy and subsequent mortality in the gen-
eral population have been mixed. In an early study using
data from the Connecticut Cancer Registry, bilateral oo-
phorectomy was associated with improved five-year sur-
vival after breast cancer diagnosis (72% versus 58%) [9].
However, in a recent analysis of data from the Nurses’
Health Study, no association was reported for bilateral
oophorectomy and hysterectomy and breast cancer mor-
tality (HR = 0.94; 95% CI: 0.70 to 1.26) based on 230
breast cancer deaths during a 24-year follow-up. Age-
adjusted hazard ratios for breast cancer mortality ranged
from 0.78 for women less than 45 years at oophorec-
tomy to 1.16 for women age 45 to 54 years at surgery
[10]. The start of follow-up was defined as the age at
Table 3 Hazard ratios (95% CI) for mortality according to age at diagnosis and follow-up period, Collaborative Breast
Cancer Studies
Person-years All-cause mortality Breast cancer mortality Cardiovascular disease mortality
Deaths HR (95% CI)a Deaths HR (95% CI)b Deaths HR (95% CI)b
Follow-up period:
5-year mortality
Intact uterus and ovaries, never hormone use 15,462 537 1 331 1 59 1
TAHBSOc 6,165 170 0.93 (0.78, 1.10) 103 0.93 (0.74, 1.16) 19 0.94 (0.55, 1.58)
TAHBSO, Never used hormones 1,857 64 0.91 (0.70, 1.19) 31 0.79 (0.54, 1.16) 10 1.14 (0.58, 2.24)
TAHBSO, Used unopposed estrogens 3,596 90 0.93 (0.75, 1.17) 61 1.03 (0.77, 1.36) 7 0.70 (0.32, 1.55)
Mortality among 5-year survivors
Intact uterus and ovaries, never hormone use 27,759 1,340 1 330 1 267 1
TAHBSOc 11,384 387 0.80 (0.72, 0.90) 95 0.81 (0.64, 1.02) 75 0.82 (0.63, 1.06)
TAHBSO, Never used hormones 3,541 177 0.82 (0.78, 1.07) 28 0.69 (0.46, 1.01) 48 1.19 (0.87, 1.63)
TAHBSO, Used unopposed estrogens 6,649 180 0.72 (0.62, 0.85) 59 0.92 (0.69, 1.23) 24 0.53 (0.35, 0.81)
Age at diagnosis:
50-64 yearsd
Intact uterus and ovaries, never hormone use 20,968 593 1 326 1 60 1
TAHBSOc 9,559 189 0.78 (0.66, 0.91) 103 0.78 (0.62, 0.98) 15 0.61 (0.34, 1.09)
TAHBSO, Never used hormones 1,890 47 0.80 (0.59, 1.08) 22 0.68 (0.43, 1.07) 6 0.97 (0.42, 2.24)
TAHBSO, Used unopposed estrogens 6,391 115 0.75 (0.61, 0.92) 68 0.85 (0.65, 1.12) 5 0.32 (0.13, 0.80)
≥ 65 years
Intact uterus and ovaries, never hormone use 22,253 1,284 1 335 1 296 1
TAHBSOc 7,990 368 0.86 (0.77, 0.97) 95 0.95 (0.75, 1.20) 79 0.90 (0.69, 1.15)
TAHBSO, Never used hormones 3,507 194 0.95 (0.82, 1.11) 37 0.76 (0.54, 1.08) 52 1.21 (0.89, 1.64)
TAHBSO, Used unopposed estrogens 3,854 155 0.80 (0.67, 0.94) 52 1.15 (0.85, 1.54) 26 0.65 (0.43, 0.98)
aHazard ratios adjusted for age, study enrollment years, state, body mass index, cigarette smoking, family history of breast cancer, and stage at diagnosis;
bcumulative incidence subhazard ratios adjusted for age, study enrollment years, state, body mass index, cigarette smoking, family history of breast cancer, and
stage at diagnosis; cTAHBSO, total abdominal hysterectomy with bilateral salpingo-oophorectomy; ddue to the low number of cardiovascular disease mortality
events among women ages 50 to 64 at diagnosis, full multivariate adjustment was not performed. CVD mortality cumulative incidence subhazard ratios are
adjusted for age, study enrollment years, and stage at diagnosis.
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surgery for oophorectomized women [10]; mortality haz-
ard ratios therefore incorporate the reduction in breast
cancer incidence associated with premenopausal oo-
phorectomy, which could reduce the death rate by low-
ering the number of breast cancers that develop initially.
In our analysis, follow-up started at breast cancer diag-
nosis; therefore, our observed associations between
TAHBSO and mortality are not influenced by the de-
creased risk of developing breast cancer associated with
TAHBSO and demonstrate survival benefits after breast
cancer has already been diagnosed.
Previous studies have suggested that use of estrogen
therapy after TAHBSO can mitigate the potential in-
creased risk of CVD associated with early surgical meno-
pause [12,14,16]. We hypothesized that women who
reported TAHBSO without estrogen use would have an el-
evated risk of cardiovascular mortality relative to the com-
parison group of women with an intact uterus and ovaries
who never used hormones. The strong inverse association
we observed between estrogen use after TAHBSO and car-
diovascular mortality among breast cancer survivors in
our study population was unexpected. Clinical trial results
have refuted a cardioprotective effect of estrogen therapy
in healthy women overall, although they have not often fo-
cused specifically on those with a prior TAHBSO [28].
One explanation of our results could be that women who
are susceptible to developing severe CVD after TAHBSO
with estrogen therapy do so prior to developing breast
cancer, which would result in the appearance of a protect-
ive effect of estrogens.
Limitations to this analysis include potential misclassi-
fication of exposure based on self-reported information.
However, our confidence in these data is strengthened
by the high reliability of the study questionnaire. In a se-
quential sample of 195 women without breast cancer
who were re-interviewed after an average of 3.5 months,
hysterectomy and oophorectomy status were highly re-
producible (κ = 0.98; 95% CI: 0.95, 1.00) [29]. Although
validation data were not available here, agreement be-
tween medical reports and self-reported bilateral oophor-
ectomy status has ranged from 70 to 96% in other studies
[30-33]. In a subset of these data [22] and elsewhere
[34-39], self-reported postmenopausal hormone use has
also been shown to be a reliable and valid measure for use
in epidemiological studies.
In the Women’s Contraceptive and Reproductive Ex-
periences case-control study, bilateral oophorectomy
was associated with stronger reductions in the incidence
of estrogen receptor (ER)+/progesterone receptor (PR)+
breast cancers (OR = 0.55; 95% CI: 0.45, 0.68) compared
to ER-/PR- tumors (OR = 0.82; 95% CI: 0.63, 1.07) [40].
In our study, information on hormone receptor status
and treatment regimen was not available; however, the
age and postmenopausal status of participants at breast
cancer diagnosis suggest that the majority were likely to
be hormone receptor positive and to have received
endocrine therapy [41]. If the inverse association be-
tween TAHBSO and mortality were limited to ER+/PR+
tumors, the inclusion of other tumor types in our ana-
lyses could have attenuated our results. Our confidence
in these results is strengthened by sensitivity analyses
demonstrating equivalent associations for local disease
only and all breast cancer diagnoses (adjusted for stage).
Our exposure assessment was based on a single inter-
view conducted approximately one year after breast cancer
diagnosis. Some study participants may have undergone
TAHBSO after this time; these surgeries would have been
performed after menopause and would likely exert a lesser
effect on mortality risk, although intact ovaries continue to
produce small amounts of androgens after menopause and
could influence chronic disease risk [42,43]. The lack of in-
formation on post-diagnosis estrogen therapy is unlikely to
be a major issue as it is generally not recommended for
women with a breast cancer diagnosis [44]. Our analyses
were specific to women with a breast cancer diagnosis at
ages 50 and older, and may not be generalizable to women
who have not had breast cancer, who were diagnosed at
younger ages, or who underwent bilateral oophorectomy
after diagnosis.
Conclusions
This analysis provides evidence of a beneficial effect of
pre-diagnosis TAHBSO on overall mortality in a large,
population-based cohort of breast cancer survivors. Given
that an estimated 15% of US women in the general popula-
tion undergo elective bilateral oophorectomy by age 60
[19], and breast cancer occurs in one in eight women dur-
ing their lifetime [1], this is not an uncommon scenario.
These findings illustrate the need to monitor both cancer
and non-cancer outcomes in breast cancer survivors.
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